Advertisement

Topics

Latest "Laureate Pharma, Inc." News Stories

22:27 EDT 18th October 2018 | BioPortfolio

Here are the most relevant search results for "Laureate Pharma, Inc." found in our extensive news archives from over 250 global news sources.

More Information about Laureate Pharma, Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Laureate Pharma, Inc. for you to read. Along with our medical data and news we also list Laureate Pharma, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Laureate Pharma, Inc. Companies for you to search.

Showing "Laureate Pharma" News Articles 1–25 of 7,700+

Thursday 18th October 2018

Santen Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27082018] Prices from USD $250

SummarySanten Inc Santen, a subsidiary of Santen Pharmaceutical Co Ltd, is a pharmaceutical company that develops, manufactures and markets ophthalmic products. The company offers products in therapeutic areas of retinal disorders, glaucoma and corneal diseases. It conducts diagnosis on uveitis conditions such as sightthreatening intraocular inflammation of autoimmune, infectious or unknown etiolo...


PTI Jumps Over 400% On CF Data, GRTS, YMAB March Ahead, NVS Acquires ECYT

The following are some of today's top gainers in the pharma/biotech sector.

Big Pharma, Little Pharma

Evolution provides options for those firms that can’t be huge


Kaken Pharmaceutical Co Ltd 4521 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryKaken Pharmaceutical Co Ltd Kaken Pharma is a pharmaceutical company that conducts research and develops drugs, agrochemicals, medical equipment and animal health products. The company offers solutions in the fields of orthopedics, dermatology, immunology, inflammation, allergies, fungal infection and pain relief. It offers streptomycin and various antifungal agents. Kaken Pharma also offer...

LISTEN: Drug prices on TV, immortal blockbusters, and genetic privacy

Are prescription drugs like new cars? Is pharma's grand bargain a sham? And who keeps your DNA safe? Find out on our biotech podcast, "The Readout LOUD."

Biotech Analysis Central Pharma News: Regeneron's Results, BMY's Failure, Novartis' FDA Rejection

Opioid Lawsuits On Par To Become Largest Civil Litigation Agreement In U.S. History

Recent months have seen a surge in opioid-related lawsuits against pharmaceutical companies and individual leadership of pharma, as well as retail pharmacies and dispensaries. Interestingly, they are being filed by cities, counties, state’s attorneys general and Native American tribal councils.

Ascletis' Ravidasvir NDA Proposed for Priority Review by the CFDA

HANGZHOU and SHAOXING, China, Oct. 18, 2018 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK) announces today the New Drug Application (NDA) of Ravidasvir is on the List of Proposed Priority Review, according to the public notification by the China Food and Drug Administration (CFDA) on Oct 17th, 2018. Such Priority Review will accelerate Ravidasvir NDA approval process significantly. Ravid...

Merck to create 170 jobs with new Ireland expansion

The big pharma has invested in its manufacturing network as demand climbs for vaccines and biologics.

Medios AG: Extension of Management Board contracts of Manfred Schneider (CEO) and Matthias Gärtner (CFO)

DGAP-News: Medios AG / Key word(s): Miscellaneous 18.10.2018 / 15:03 The issuer is solely responsible for the content of this announcement. Corporate News   Medios AG: Extension of Management Board contracts of Manfred Schneider (CEO) and Matthias Gärtner (CFO)​ Berlin, 18 October 2018 - The Supervisory Board of Medios AG ('Medios'), one of the leading Specialty Pharma compani...

Acacia Pharma pitches quick path to refiling Barhemsys

A Complete Response Letter from the FDA earlier this month derailed Acacia's plans for its lead drug, but it hopes to soon get back on track.

NeuroActiva looks to raise up to $200m by mid-2019 for Alzheimer’s trial

NeuroActiva is actively discussing either a large pharma partnership or a potential NASDAQ public listing (IPO) by mid-2019 to raise...Read More... The post NeuroActiva looks to raise up to $200m by mid-2019 for Alzheimer’s trial appeared first on Pharmaceutical Technology.

Noxxon Pharma AG Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryNoxxon Pharma AG Noxxon is a clinical stage biotechnology company that develops and provides drugs for the treatment of cancer. The company develops therapeutics for the treatment of inflammatory diseases and hematological disorders, diabetes and renal diseases, oncology, inflammation and pain. Its pipeline products include NOXA12, used for the treatment of metastatic pancreatic and colorec...

FORTUNE and Great Place to Work® Name Horizon Pharma plc to 2018 Best Small & Medium Workplaces for Third Consecutive Year

Horizon Pharma plc (Nasdaq: HZNP) today announced that it has been named one of the 2018 Best Small & Medium Workplaces by FORTUNE and Great Place to Work® for the third consecutive year. “We are honored that FORTUNE and Great Place to Work has again named Horizon Pharma as one of its Best Workplaces,” said Timothy P. ...

Managing inventory: What retail can learn from pharma

Retail and pharma are vastly different industries. But the tightly controlled world of drug supply still holds lessons for consumer goods. 

Drug Prices In Ads Could Cause Sticker Shock For Consumers, Forcing Pharma To Tinker With Marketing Strategies

Experts don't predict the proposed requirement would cause a broad pullback of ad campaigns, but companies will have to make some tough, and possibly expensive, choices. Meanwhile, President Donald Trump hints at a big win for drugmakers with a big change to Medicaid's rebate rule.

GW Pharma Pipeline Will Add To Bottom Line And Stock Price

Novartis to buy cancer drug firm Endocyte for $2.1bn

Novartis has announced plans to buy cancer drug firm Endocyte for $2.1 billion cash. The Swiss pharma giant is buying the US-based Endocyte to expand its radiopharmaceuticals business. News of the plans sent Endocyte’s shares rocketing by 49.74...

Join us on the 6th of November 2018 for our free webinar on Rare Diseases in the Middle East and North Africa, an area with a population of more than 400 million and a high incidence of rare diseases. Register now at https://lnkd.in/gtSSCJZ  #RareDiseas

Join us on the 6th of November 2018 for our free webinar on Rare Diseases in the Middle East and North Africa, an area with a population of more than 400 million and a high incidence of rare diseases. Register now at https://lnkd.in/gtSSCJZ  #RareDisease #MENA #pharma pic.twitter.com/HhaKc2rdKV

MHRA to extend EpiPen expiry dates to tackle shortages http://bit.ly/2pXQ25F  #EpiPen #MHRA #UK #pharmapic.twitter.com/Z4xsrpovTp

MHRA to extend EpiPen expiry dates to tackle shortages http://bit.ly/2pXQ25F  #EpiPen #MHRA #UK #pharma pic.twitter.com/Z4xsrpovTp

Pfizer announce cull of 2% of staff http://bit.ly/2AgLn4J  #Pfizer #Jobs #pharmapic.twitter.com/G43xIIMTa0

Pfizer announce cull of 2% of staff http://bit.ly/2AgLn4J  #Pfizer #Jobs #pharma pic.twitter.com/G43xIIMTa0

Innovus Pharma Announces Planned Expansion into CBD Oil-Based Products Market

– First Product MZS Sleeping Aid™ Currently Expected to Launch in the U.S. in Q4 2018 Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve...

Novartis snaps up cancer drug developer Endocyte for $2.1 billion

Novartis will shell out $2.1 billion to acquire cancer drug developer Endocyte in a move to leverage the company’s technology to investigate potential development of therapies in prostate cancer, it has emerged. The deal will see Novartis acquire all of Endocyte’s outstanding shares of common stock for $24 per share, equating to the valuation of $2.1 billion, and will allow the pharma giant to...

Novartis buys Endocyte for $2.1B in latest deal under CEO Narasimhan

The acquisition, announced as Novartis reported third quarter earnings, adds another radioligand therapy to the Swiss pharma's pipeline. 

Cigalah Medpharm Announces the Launch in Saudi Arabia and United Arab Emirates of Nexodyn® AOS, the Tehclo-Based Wound Cleanser Developed by the Swiss Pharma Company APR

Nexodyn® AcidOxidizing Solution (AOS), the Tehclo-based cleanser for acute and chronic wound management, is now starting to be available in Saudi Arabia and United Arab Emirates (UAE), promoted and commercialized by the leading pharmaceutical company Cigalah Medpharm, part of Cigalah Group, following an exclusive partnership with the Swiss Pharma company ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks